The suit also contends that the study's"flexible protocol," which allowed patients to adjust their dosage, compromised the trial's ability to assess weight loss at the tested dosage accurately. This, the plaintiffs suggest, implies either unexpected tolerability issues that led patients to reduce their doses or a rushed patient selection process that included those not targeting the 25% weight loss goal. The complaint points to Novo Nordisk's December 20, 2024, announcement of REDEFINE-1's preliminary results. The disclosure indicated that the trial used a flexible dosing protocol and revealed that, after 68 weeks, only 57.3% of CagriSema patients were on the highest dose, compared to 82.5% for cagrilintide and 70.2% for semaglutide, the comparator drugs. Following the announcement, Novo Nordisk's stock price plunged nearly 18%, according to the lawsuit. The plaintiffs argue that this drop highlights the impact of the alleged misrepresentations on investors.